Oramed Pharmaceuticals
ORMP
21 hedge funds and large institutions have $1.85M invested in Oramed Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 8 closing their positions.
0.72% less ownership
Funds ownership: 2.64% → 1.92% (-0.72%)
22% less funds holding
Funds holding: 27 → 21 (-6)
46% less capital invested
Capital invested by funds: $3.4M → $1.85M (-$1.56M)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
95% less call options, than puts
Call options by funds: $1K | Put options by funds: $20K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$50.5K |
| 2 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$17.3K |
| 3 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$3.86K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.16K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$183K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$166K |
| 3 |
Millennium Management
New York
|
-$143K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$116K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$88.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$32K | -3,499 | Closed |
|
27
JP Morgan Chase
New York
| – | -$15K | -1,700 | Closed |
|
|
CA
28
Calton & Associates
Tampa,
Florida
| – | -$3K | -450 | Closed |
|
|
LC
29
Landaas & Company
Milwaukee,
Wisconsin
| – | -$2K | -230 | Closed |
|
ORMP Hedge Fund Activity: Q1 2018 in Review
21 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q1 2018, worth a combined $1.85M — down 46% from $3.4M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ORMP and 2 opened new positions — a net loss of 6 holders — while 5 trimmed existing stakes and 2 added.
The largest buyer was Citigroup, opening a new position worth an estimated $50.5K. The largest seller was Renaissance Technologies, cutting an estimated $183K.
- 21 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q1 2018, down from 27 in Q4 2017.
- Funds reported $1.85M of Oramed Pharmaceuticals stock for Q1 2018, down 46% quarter-over-quarter.
- 2 funds opened new Oramed Pharmaceuticals positions in Q1 2018 and 8 closed out, a net change of -6 holders.
- The largest Oramed Pharmaceuticals buyer in Q1 2018 was Citigroup, an estimated $50.5K added.
- The largest Oramed Pharmaceuticals seller in Q1 2018 was Renaissance Technologies, an estimated $183K sold.
Based on aggregated 13F filings for Q1 2018.